A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine whether LY2181308 in combination with
docetaxel is safe and effective treatment for hormone refractory prostate cancer patients.